Drug Interactions between dutasteride / tamsulosin and vorasidenib
This report displays the potential drug interactions for the following 2 drugs:
- dutasteride/tamsulosin
- vorasidenib
Interactions between your drugs
tamsulosin vorasidenib
Applies to: dutasteride / tamsulosin and vorasidenib
GENERALLY AVOID: Concomitant use with multiple doses of vorasidenib may decrease the plasma concentrations of drugs that are substrates of CYP450 3A. Vorasidenib is predicted to be an inducer of CYP450 3A resulting in decreased plasma concentrations of agents that are metabolized by the isoenzyme. The interaction may be significant for sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index. Clinical and pharmacokinetic data are currently lacking.
MANAGEMENT: Concomitant use of vorasidenib with substrates of CYP450 3A should be avoided due to the potential for reduced efficacy
References (2)
- (2024) "Product Information. Voranigo (vorasidenib)." Servier Pharmaceuticals LLC
- Multicenter Study Group (2024) Center for drug evaluation and research. Application number: 218784Orig1s000. Integrated review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/218784Orig1s000MultidisciplineR.pdf
dutasteride vorasidenib
Applies to: dutasteride / tamsulosin and vorasidenib
GENERALLY AVOID: Concomitant use with multiple doses of vorasidenib may decrease the plasma concentrations of drugs that are substrates of CYP450 3A. Vorasidenib is predicted to be an inducer of CYP450 3A resulting in decreased plasma concentrations of agents that are metabolized by the isoenzyme. The interaction may be significant for sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index. Clinical and pharmacokinetic data are currently lacking.
MANAGEMENT: Concomitant use of vorasidenib with substrates of CYP450 3A should be avoided due to the potential for reduced efficacy
References (2)
- (2024) "Product Information. Voranigo (vorasidenib)." Servier Pharmaceuticals LLC
- Multicenter Study Group (2024) Center for drug evaluation and research. Application number: 218784Orig1s000. Integrated review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/218784Orig1s000MultidisciplineR.pdf
Drug and food interactions
tamsulosin food
Applies to: dutasteride / tamsulosin
ADJUST DOSING INTERVAL: Food may delay the gastrointestinal absorption of tamsulosin. The time to maximum plasma concentration (Tmax) is reached by 4 to 5 hours under fasted conditions and by 6 to 7 hours when tamsulosin is administered with food. The delay in Tmax has the desirable effect of smoothing the tamsulosin plasma concentration profile, thereby reducing fluctuation of the plasma peak and trough concentrations with multiple dosing. Food may also affect the extent of absorption of tamsulosin. It has been reported that taking tamsulosin under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak plasma concentration (Cmax) compared to fed conditions. The effects of food on the pharmacokinetics of tamsulosin are consistent regardless of whether tamsulosin is taken with a light meal or a high-fat meal.
MANAGEMENT: To ensure uniformity of absorption, tamsulosin should be administered approximately one-half hour following the same meal each day.
References (1)
- (2001) "Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim
vorasidenib food
Applies to: vorasidenib
GENERALLY AVOID: Due to induction of CYP450 1A2, the isoenzyme primarily responsible for the metabolic clearance of vorasidenib, smoking tobacco during treatment with vorasidenib may decrease its plasma concentrations and anti-tumor effect. Clinical and pharmacokinetic data are currently lacking.
MANAGEMENT: Patient should be advised to avoid smoking tobacco during treatment with vorasidenib because it may reduce efficacy of the therapy.
References (1)
- (2024) "Product Information. Voranigo (vorasidenib)." Servier Pharmaceuticals LLC
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.